The current standard first-line treatment for microsatellite stable/proficient mismatch repair (MSS/pMMR) mCRC patients is essentially represented by a fluoropyrimidine (5-FU or capecitabine) combined with irinotecan and/or oxaliplatin, together with either the anti-VEGF bevacizumab or an anti-EGFR, according to patient and tumor characteristics [32]. The gene discussed is EGFR; the disease is neoplasm.